Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR2 | Q8NFJ6 | 4/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 8/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518617 | 0.88 | PROKR2 (0.68) | PROKR2KDM4ELMNADRD4MCHR1 | |
| SCHEMBL3517610 | 0.88 | PROKR2 (0.66) | PROKR2KDM4EMCHR1MEN1KMT2A | |
| SCHEMBL3517284 | 0.88 | PROKR2 (0.66) | PROKR2KDM4EPDCD1CD274LMNA | |
| SCHEMBL3524424 | 0.88 | PROKR2 (0.66) | PROKR2KDM4EMCHR1MEN1KMT2A | |
| SCHEMBL3521885 | 0.88 | PROKR2 (0.83) | PROKR2KDM4EDRD4MCHR1KMT2A | |
| SCHEMBL3520056 | 0.88 | PROKR2 (0.83) | PROKR2KDM4EDRD4MCHR1KMT2A | |
| SCHEMBL20936096 | 0.87 | PROKR2 (0.82) | PROKR2KDM4EPDCD1CD274DRD4 | |
| SCHEMBL3517978 | 0.87 | PROKR2 (0.65) | PROKR2KDM4EPDCD1CD274LMNA | |
| SCHEMBL3518632 | 0.87 | PROKR2 (0.64) | PROKR2KDM4EPDCD1CD274LMNA | |
| SCHEMBL3518689 | 0.87 | PROKR2 (0.64) | PROKR2KDM4EPDCD1CD274LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1959959-B1 | MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-04-10 | — | — | EP | claimed |
| US-7855201-B2 | Morpholine carboxamide prokineticin receptor antagonists | Merck Sharp & Dohme. Corp. (US) | 2010-12-21 | — | — | US | claimed |
| US-20090306076-A1 | Morpholine Carboxamide Prokineticin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-12-10 | — | — | US | claimed |
| EP-1959959-A2 | MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| WO-2007067511-A2 | MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-06-14 | — | — | WO | claimed |
| EP-1959959-B1 | MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-04-10 | — | — | EP | disclosed |
| US-7855201-B2 | Morpholine carboxamide prokineticin receptor antagonists | Merck Sharp & Dohme. Corp. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20090306076-A1 | Morpholine Carboxamide Prokineticin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306076-A1 | Morpholine Carboxamide Prokineticin Receptor Antagonists | PROKR2, PROKR1, NTSR2 | PROKR2 1/4885KDM4E 4734/4885PDCD1 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.